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ABSTRACT 
 
 
 
Anti-Tumor Natural Products Research Focused on Plants Found in the Southern 
Appalachian Region 
Matthew John Flood II 
Western Carolina University (July 2010) 
Director:  Dr. Jason Clement 
Natural products have been an integral part of society since the beginning of recorded 
history.  Various types of herbs, plants, and even marine organisms have been used as 
both topical and ingestible remedies for a variety of health concerns and problems 
throughout the years.  Our research efforts focus on the isolation and characterization of 
antitumor compounds from plant extracts from western North Carolina, a surprisingly 
diverse and under studied region of the country.  Recent work has been done on the plant 
species Aralia racemosa and Arnoglossum atriplicifolium.  Crude extracts were initially 
separated using either a modified Kupchan Partitioning or standard acid/base extr ction, 
and then further purified using various chromatographic techniques.  Two compounds 
resulted from this work on the two species and were characterized using various methods 
of mass spectrometry, and advanced NMR experiments including COSY, HMBC, and 
HSQC.  An ent-kaurane diterpenoid was isolated from Aralia racemosa, and a highly 
oxygenated oplopane derivative from Arnoglossum atriplicifolium.   The activity of the 
compounds was determined through a MCF-7 assay (breast cancer), with the control 
group being a FS-4 assay, both carried out by Wake Forest University.  This is the fir t 
report of the antitumor activity of each of these compounds. 
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1.  OVERVIEW OF PREVIOUS NATURAL PRODUCT STUDIES AND 
OVERVIEW OF METHODOLOGY 
 
 
 
1.1 Introduction to Natural Products 
Natural products have been an integral part of society since the beginning of 
recorded history.  Various types of herbs, plants, and even marine organisms have been 
used as both topical and ingestible remedies for a variety of health concerns and problems 
throughout the years.  However, around the turn of the nineteenth century, research 
started to focus on isolating and purifying compounds from natural sources as opposed to 
just accepting the medicinal powers of crude extracts.  The methods and ideas of trying to 
isolate compounds that are already present in nature has continued on into areas of 
present day chemical research and development.1  Natural products research has 
introduced many revolutionary products into modern medicine during its history.  Natural 
products chemistry has brought forth compounds that have gone on to eventually lead to 
advanced cancer treatments, pain relievers, dietary supplements, and the treatmen  of a 
wide range of health issues. 
Much of current natural product research is focused on finding effective cancer 
treatments.  Cancer has become a main interest of natural products chemistry over he 
years due to its widespread diagnosis.  In the United States alone one out of every four 
deaths can be attributed to cancer, making it second only to heart disease as the lading 
cause of death in America.2  
The isolation and characterization of biologically active compounds from natural 
sources is called pharmacognosy.  In pharmacognosy, there are three main areas of
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inquiry: extraction, biological evaluation of extracts, and isolation/characteriza ion of 
active principles of the extracts.  Pharmacognosy differs from the more basic form of 
natural products chemistry, phytochemistry, which focuses solely on extraction, isolation, 
and characterization of compounds that may serve as taxonomic markers.  Our research 
efforts will focus on the isolation and characterization of antitumor compounds from 
plant extracts from western North Carolina.   
The isolation and characterization of a pure compound from a crude extract can 
be a fairly lengthy process.  The main guiding factor in these isolations is the use of 
bioassays.  A bioassay is a way to test biologically active compounds against a specific
biological system.  Initially a crude extract is prepared and tested against one or more 
bioassays to check for bioactivity.  If the results are positive, further testing i  required to 
find the responsible compound(s).  In our case, if a crude sample is found to inhibit 
proliferation of MCF-7 cells, it is sent to our research labs to isolate the biological y 
active compounds.  Once the crude sample is obtained, it needs to be fractionated, usually 
through multiple steps of liquid chromatography.  Once the initial fractions are prepared 
they are run against the bioassays to test for activity.  This is done to ensure that time is 
not wasted isolating inactive compounds.  When active sub-fractions are obtained, they 
are tested in the assay to confirm the activity of the parent fractions.  If the purified 
compounds show promise from the assays, they are characterized and their structure is 
determined using various spectroscopic methods.  Once a biologically active natural
product has been isolated and shows promising biological activity, it is often 
synthetically produced in larger quantities.  This is necessary because in most cases there 
is simply not enough of the natural source material to supply the drug companies for 
10 
 
 
mass production.  To try and replicate or improve upon the original molecule’s success, 
synthetic derivatives may also be developed and tested.  A synthetic approach that is 
affordable and more time efficient than isolation methods is desirable to pharmaceutic l 
companies in order to make the drug(s) more marketable to the public.   
The search for an effective cure for cancer has been a major goal in 
pharmaceutical research for quite some time and will most likely continue to be until a 
reliable and definite cure has been found or cancer has been made manageable.  Many 
compounds that have already been isolated have shown great promise in helping the fight 
against cancer.  The real test is to find compounds that are biologically selective to fight 
cancer, that is to say the compounds selectively fight the cancer cells as opposed to 
simply killing all cells.  These types of compounds are desirable because if the isolated 
compounds destroyed all cells (both tumorous and healthy) they are of little use to the 
pharmaceutical industry.  While many of the compounds that have gone on to clinical 
trials do not fully meet these standards, they do possess the ability to fight off cancerous 
cells while preserving the majority of healthy cells.  Of these molecules which have been 
isolated, many have continued on to clinical trials and also into the market.  Although the 
current drugs have shown promise and are somewhat effective, researchers are still 
looking for more selective drugs that prolong life and improve the quality of life for 
cancer patients.  The most successful anti-tumor natural products are briefly reviewed in 
section 1.2. 
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1.2  Background 
1.2.1  Taxol  
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1.1 
 Taxol (1.1) was first discovered and isolated in the late 1960’s from the stem bark 
of Taxus brevifolia (Western yew).  The compound was of great interest to scientists as it 
showed potent anti-leukemia and anti-tumor properties in cell assays.3  Since the first 
isolation, taxol has also been isolated from other sources including the endophytic tree 
fungi Taxomyces andreanae nd Bartalinia robillardoides.4 
 The mechanism used by taxol to inhibit cell growth was unique at the time of its 
discovery.  The compound works to inhibit the depolymerization of microtubules into 
tubulin during cell division.  Under normal circumstances microtubules will 
depolymerize back to tubulin upon command allowing the cell to further multiply.  
However, taxol works to inhibit the breaking down of microtubules inside the cell which 
prevents the cell from further dividing (mitosis).4  
 The major problem that held taxol back from becoming a very viable factor in 
fighting cancer was availability.4  Natural taxol requires 60,000 pounds of bark from 
12,000 trees which only produce 2.5 kilograms of taxol.  Production levels like these 
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cannot be sustained because of the risk posed to the Western Yew tree.  These 
shortcomings led to the development of syntheses of taxol, the most well known being a 
semisynthesis of taxol from 10-deacetylbaccatin III by Dr. Robert A. Holton’s research 
group at Florida State University in the late eighties.  This allowed taxol o be produced 
on a larger scale and at more reasonable prices to both consumers and producers.5  
Currently, taxol is being marketed under the generic name paclitaxel, and is use  
mainly to treat ovarian, breast, and lung cancers.  Due to taxol’s poor water solubility, the 
drug has poor bioavailability in patients.  This problem has led to the development of 
analogs like Docetaxel, a more potent and more water-soluble synthetic analog, which in 
essence uses the same mechanism to fight advanced breast cancers and also lu g cancer.6 
1.2.2  Camptothecin 
N
N
O
O
OOHCH3  
    1.2 
 Camptothecin (1.2) was initially isolated from the wood and bark of Camptotheca 
acuminata, a tree found in China.  The compound was found to have a very high activity 
against L1210 and P388 leukemia cell assays.  These promising experimental results ed 
to clinical trials involving camptothecin. 7 
 The clinical trials of camptothecin showed promise in both phase 1 and 2 trials 
when paired with a campthothecin sodium salt (Phase 1 and 2 trials being the earliest
tests of a drug’s effects and efficacy).  The compound was found to be effective against 
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gastric, intestinal, head, and neck tumors.  The mechanism of action was later found to be 
inhibition of the enzyme topisomerase I, an enzyme that has been shown to play a role in
DNA replication, transcription, and recombination, therefore inhibiting tumor growth. 7 
Upon further study camptothecin was also found to be useful in the fight against 
otherwise resistant breast cancers.  However, the drug never made it to clinical use due to 
more successful analogues being developed that were close to ten times as powerful.8,9  
First generation synthetic derivatives were eventually developed and marketed tha  
included both Topotecan and Irinotecan, more water soluble versions of the natural 
product, making the drugs easier to administer.  Both drugs are used for ovarian and 
colon cancer treatment.  Camptothecin research has continued as scientists believe that 
the effects of the mechanism (specifically as a topisomerase I poison) have not yet been 
fully realized and second generation analogues are currently under development. 6 
1.2.3  Podophyllotoxin 
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 Podophyllotoxin (1.3), a lignan found in the resin of the dried roots of the plant 
Podophyllum peltatum (commonly known as mayapple), commonly found in the eastern 
United States, is another natural product that has come into focus in recent years.10  The 
compound was first used during the nineteenth century to treat various diseases, venereal
warts, and syphilis along with other ailments, which has led to more recent studies on th  
drug.11 
 As its mechanism of action, podophyllotoxin works to inhibit the polymerization 
of tubulin.  Unlike taxol, where the compound prevents the breaking down of the 
microtubules inside the cell, podphyllotoxin prevents microtubule formation from 
tubulin.  If the microtubules (or spindles) are unable to form, then the cell is unable to 
divide the cell’s chromosomes, resulting in sudden apoptosis of the cell in the 
metaphase.9 
 While podophyllotoxin was thought to be a promising and effective anti-tumor 
agent as clinical trials began, the compound was soon found to create severe 
gastrointestinal problems in patients.  These disappointing results led scientists to ry and 
develop synthetic derivatives that were more “patient-friendly.”  Etoposide (1.4) and 
teniposide (1.5) were eventually synthetically derived from the basic structure of 
podophyllotoxin, and were found to be more successful in clinical trials.12 
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1.2.4  Vinca Alkaloids 
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 The vinca alkaloids, vinblastine (1.6)  and vincristine (1.7), were both isolated 
from the leaves of the Catharanthus roseus, commonly known as the Madagascar 
periwinkle.  Vincristine was found to be effective against non-Hodgkin’s lymphoma in 
clinical trials, while vinblastine was also found to be effective against non-Hodgkin’s 
lymphoma along with breast, testicular, bladder, and lung cancers.13  The mechanism of 
action of the vinca alkaloids to inhibit these various diseases is the inhibition of tubulin 
polymerization in the cell.  This in turn makes it impossible for the cell to divide, which 
then proceeds to apoptosis.12,14 
 The mass production of the vinca alkaloids has been difficult, as it takes a large 
amount of plant to obtain either of the vinca alkaloids (about 3 g are produced per metric 
ton of Madagascar Periwinkle).  Scientists have dealt with this shortcoming by resorting 
to producing the compounds through mass cultivation, as the Periwinkle is a very easy 
and quick plant to grow.12,13 
 Natural products chemistry has become a mainstay in the pharmaceutical 
industry, and especially in anti-tumor research.  Along with the previous compounds, 
natural products research has brought about many new and successful treatments in o all 
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fields of medicine.15  Our research group will continue to focus on the discovery and 
isolation of new compounds effective in the treatment of breast cancer, in hopes of 
finding a lead in the creation of a new anti-tumor drug/treatment. 
1.3  Overview of Methods  
 The separation of natural products relies heavily on different forms of liquid 
chromatography.  Methods that include open-column chromatography, high performance 
liquid chromatography (both normal and reverse phase), along with liquid partitioning are 
implemented in order to purify compounds of interest.  Once a specific compound has 
been isolated, we are then able to use nuclear magnetic resonance (NMR) spectroscopy, 
mass spectrometry, and various other spectroscopic methods in order to characterize nd 
identify the compound of interest. 
1.3.1  Liquid Chromatography 
 Chromatography is a method of separation used by scientists to obtain fractions 
and also pure compounds out of crude extracts.  Separations are completed through the 
use of a mobile phase being passed through the stationary phase in a column.  Stationary 
phases can be made up of a variety of substances including silica gels and synthetic 
polymers. 16   
Silica gels rely on polarity differences in order to separate substance eluting from 
the column.  Silanol groups in the gel tend to have higher dipole moments allowing 
sample groups with complementary dipole moments to be attracted to these stationary 
phase groups.  These polarity differences allow for the sample groups with higher 
polarities to remain bound to the stationary phase longer, and therefore elute slower.13  
One of our more frequently used techniques for separating extract fractions is a reverse-
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phase C18 silica column.  Reverse-phase chromatography differs from normal-phase 
chromatography in the fact that it elutes compounds in the reverse order as normal phase 
under most circumstances.  Generally, in reverse phase the more hydrophilic compounds 
are eluted first followed by the more hydrophobic compounds.  Hydrophobic compounds 
tend to hang on to the long carbon chains of the C18, due to London dispersion forces, 
longer than the hydrophilic compounds which elute fairly quickly.16,17    
Some synthetic polymers can also work as chromatography stationary phases by  
size exclusion mechanism.  Size exclusion basically works around the idea that larger 
particles will pass through the column quicker that smaller ones.  While not as efficient as 
other forms of liquid chromatography, these polymers allow for delicate samples to b  
separated with less fear of the sample decomposing as can sometimes happen with other 
forms of liquid chromatography.16 
 For the purposes of our research, high performance liquid chromatography will be 
the most useful tool.  HPLC basically follows the same principles as normal liquid 
chromatography, except the technique usually involves the use of a smaller particle
packing in the column at a higher pressure.  HPLC results in much more efficient 
separations, which is very appealing to researchers with limited amounts of time, 
resources, and samples.13  If sample size is not an issue, a preparative HPLC column can 
be used, which allows for a larger sample size to be used at a higher flow rate.  This 
process allows for separations to be performed at a higher efficiency.16 
1.3.2  Bioassay Guided Fractionation 
 Bioassay guided fractionation is a technique aimed at isolating bioactive 
compounds in a quick and effective manner.  The basis behind the idea is that the 
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biologically active compounds are only present in active fractions as determined through 
the assays, so we focus on these select fractions to find the compounds of interest.  The 
crude sample is fractionated and screened by the bioassay.  Inactive fractions re then set 
aside.  The process of removing the inactive fractions prevents the isolation of any non-
active compounds and usually only active fractions are obtained. The idea is the non-
active fractions are uninteresting and are subsequently removed from the process.  Th  
remaining known active fractions are then fractionated further and resulting sub-fractions 
are tested for activity.  By this iterative process of fractionating only active fractions, the 
active compounds are isolated from the crude extract while less interesting compounds 
are eliminated.  The isolations are tested along the way to see if they are selectively 
cytotoxic against both healthy and tumor cells. 
While we usually assume that only one compound is responsible for the activity 
in these assays, this is not always the case.  It has been theorized that multiple compounds 
can combine to have a greater biological activity, a process known as synergi m.  This 
suggests that it is also necessary to examine multiple compound combinations in assays 
to see how compounds work with each other.  Our collaborators at the Bent Creek 
Institute are interested in the study of synergistic mixtures as a partof plant-based 
medicines, so we will therefore be including them as part of our research plan.18  For the 
purpose of our research our fractions and pure compounds will be tested in the FS-4 and 
MCF-7 cell assays.  FS-4 cells are wild-type, non-tumorous human foreskin fibroblast 
cells, while MCF-7 is an estrogen receptor-positive breast tumor cell line.19,20   
The MCF-7 assay is an MTS assay that works off the reduction of a tetrazolium 
salt to a colored (purple) formazan product.  The reduction is driven by a reductase 
19 
 
 
enzyme found only in viable cells.  Cells that do not reduce the salt are not considered 
viable, and therefore the inhibition of cell proliferation by the fraction being tested can be 
measured.     
 
 
 
 
 
 
Figure 1.1:  Reduction of Tetrazolium Salt to Formazan Product 
 
 
 
1.3.3  Mass Spectrometry 
 Mass spectrometry is a technique used to identify the molecular formula of 
analyte molecules.  The instrument we will be using for the mass spectrometry e ploys 
the electrospray ionization technique to produce ions for analysis.  Electrospray 
ionization works to turn a sample into an aerosol form and then produces ions by 
inducing a large charge into the sample droplets.  The droplet is then subjected to a 
drying gas (usually N2) in order to remove any excess solvent.  As evaporation of the 
remaining solvent continues on the droplets, eventually the electrostatic repulsions 
between the concentrated droplets become too great and cause the droplet to break apart 
into ions.  The ions are then accelerated to the quadrupole ion-trap where they are trapped
and separated by their mass-to-charge ratio (m/z), by a mass filter. 21  The ions are then 
filtered, detected, and reported by their abundances when they impact the detector and 
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electron multiplier and the mass-to-charge ratio is determined.  Although mass 
spectrometry is a very useful and efficient tool for molecule analysis, it usually cannot be 
used to determine the complete structure of organic molecules because it provides no 
information about the actual absolute configuration of the molecule.  Due to this 
restriction mass spectrometry is primarily a confirmatory tool in our lab. 16        
1.3.4  NMR 
 Nuclear magnetic resonance is our primary tool in determining the structure of 
our unknown compounds.  The  basis of NMR deals with the total spin and magnetic 
dipoles of atomic nuclei.  NMR spectroscopy deals with the study of nuclear spin of 
atoms when exposed to a magnetic field.  This phenomenon can be applied to help 
decipher atomic structures through the orientations of their respective magntic moments.    
NMR is very helpful in determining the structures of molecules, as it measures the 
respective resonances of different nuclei in different positions and analyzes their 
interactions.  The study of these resonances helps us deduce the locations of different
atoms in the molecule.22  Our research will mainly use 1H NMR along with 13C NMR, 
which measure the effects produced by hydrogen nuclei and carbon nuclei respectively.  
While these 1D NMR experiments provide much information about the structure of a 
molecule, they oftentimes do not supply enough information to obtain a complete 
structure.  To obtain complete molecular structure 2D NMR spectroscopy is used, which 
correlates data from 13C and 1H NMR spectra.  These spectra provide us with information 
about C-H connectivity and interactions, which allows us to assign a structure to our 
isolated compound in three dimensions. 23 
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 There are four main types of advanced NMR experiments used in our research: 
DEPT-135, COSY, HSQC, and HMBC.  DEPT-135 is a carbon experiment that is used to 
distinguish between methines, methylenes, and methyls while quaternary carbons do not 
appear in the spectrum.  Carbons are differentiated by their orientation relative to the 
baseline.  Methines and methyls are shown in an “up” orientation or “positive,” while 
methylenes are shown as “down” or negative.  The COSY experiment allows for proton 
to proton spin-spin coupling to be detected.  Signals in COSY tend to arise from 
neighboring protons that are two or three bonds apart, however any system with spin-spin 
coupled protons can give a COSY correlation.  The HSQC experiment allows for the 
determination of one bond couplings between hydrogens and carbons.  The experiment is 
useful in assigning protons to their respective carbons and vice versa.  The HMBC 
experiment measures long-range couplings between carbons and protons, while 
suppressing the one bond HSQC correlations.  HMBC allows for two to three bond 
correlations to be observed in the molecule of interest.  In certain, more rare conditions it 
is possible to observe four and five bond correlations using the HMBC experiment. 
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2. ISOLATION AND CHARACTERIZATION OF 17-HYDROXY-16α-ENT-
KAURAN-19-AL, A DITERPENOID FROM THE PLANT ARALIA 
RACEMOSA 
 
 
 
2.1 Introduction 
 Aside from a few phytochemical studies, the chemistry of the plant Ar lia 
racemosa has not been fully characterized up to this point.  Using an assay for the breast 
cancer cell line MCF-7, the nt-kaurane diterpenoid 17-hydroxy-16α-ent-kauran-19-al 
was isolated from an extract of the plant Aralia racemosa by bioassay-guided 
fractionation.  Characterization was completed using various 1D and 2D NMR 
experiments, along with mass spectrometry.   
2.1.1 Previous Investigation into Aralia species 
There are many plant species in the southern appalachian region that have not 
been fully characterized chemically.  Previously, the genus Aralia has yielded promising 
results in a variety of assays, with activities ranging from anti-inflammatory properties to 
hepatitis and diabetes treatments.  The species A. racemosa has been studied very little up 
to this point, with research mainly focusing on phytochemical studies.24  The previous 
history of the genus and biological activity found in these types of plants, along with the 
lack of study of the plant Aralia racemosa specifically, make it a prime candidate for our 
research. 
Many different types of compounds have been isolated from the Aralia species 
including sterols,26 falcarindiols,27 saponins, and terpenes, all of which have shown some 
kind of biological activity in vitro.28  One important set of compounds are the sterols 
23 
 
 
found in Aralia cordata, a commonly studied species.  Ik Soo Lee et al. isolated and 
characterized four sterols from the plant including 3β, 5α-dihydroxy-6β-methoxyergosta-
7,22-diene (2.1), which showed significant cytotoxicity against murine L1210 leukemia 
cells, human K562 cells, and mouse LLC Lewis lung carcinoma cells with IC50 (µM) 
values of 11.7, 11.9, and 15.1 respectively.  Other sterols isolated from the A. cordata 
yielded similar structures and showed less activity.25  Also according to older results 
compound 2.1 exhibited cytotoxicity against small cell lung, ovarian, skin, and colon 
cancers.26   
OH
CH3
OH
O
CH3
CH3
HH
CH3
CH3
CH3 CH3
 
2.1 
The falcarindiol (2.2 and 2.3) derivatives found in Aralia cordata have shown to 
be quite effective in inhibition of the COX-1 enzyme in vitro, with IC50 ranging from 
11.7 to 50.4 µM. COX-1 and COX-2 are well known for their role in the biosynthesis of 
prostaglandins and thromboaxanes from arachidonic acid, which if inhibited can have 
analgesic and antipyretic effects on the target.  The absolute configuration of these 
falcarindiol derivatives was not reported by Dang et al.27 
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 The triterpene saponin 2.4, isolated from the root bark of Aralia dasyphylla, is a 
oleanic based saponin isolated by Kai Xiao et al.  This triterpene saponin isolated showed 
significant activity against two separate cultured human cancer cell lines.  The compound 
exhibited very good potency with a IC50 values of 1.2 µM and 0.02 µM for the KB  
mouth cancer) and Hela-S3 (cervical cancer) respectively.
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     2.4 
The Aralia species also synthesizes many different derivatives from the ent-
kaurane diterpenoid skeletal structure.  Many of the derivatives are active against the 
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COX-1 and COX-2 enzymes previously mentioned, making them possible analgesic and 
antipyretic (fever-reducing) agents. 
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 Specifically Ik Soo Lee t al.  isolated compound 2.5 from the aerial parts of Aralia 
cordata, which was found to be somewhat active inhibiting the COX-1 enzyme with an 
IC50 of 227 µM.
25  Another derivative of the above skeleton was isolated and found to 
inhibit the COX-1 and COX-2 enzymes with IC50 values of 121.6 and 127.6 µM 
respectively.27   
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2.2 Results and Discussion 
2.2.1 Isolation and Characterization of 2.9 
 The isolation of 2.9 is depicted in Figure 2.1.  The plant material and crude extract 
were collected and prepared by the Bent Creek Institute.  The crude extract was subjected 
to a standard acid/base extraction, resulting in three fractions.  The Aralia racemosa 
acidic fraction showed promising activity in the MCF-7 cell assay, with an IC50 = 87.5 
µg/mL, while the other two fractions were set aside for later study.  Preliminary 
fractionation was completed by Tim Willis and Sara Garrett in the Clement Lab using 
reverse phase C18 open column chromatography with a step-gradient solvent system.  The 
80% MeOH/H2O fraction was chosen for further study due to increased activity when 
compared to other fractions and amount available for study.  The 80% MeOH/H2  
fraction was then subjected to reverse phase C18 HPLC using an 84% MeOH/H2O 
method, and compound 2.9 was isolated from the fraction. 
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Figure 2.1:  Isolation of 2.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Assay data shown is percent inhibition as determined at a sample concentration of 100 
µg/mL unless otherwise noted.  
B (CH2Cl2)
-  13.1 mg
    A (CH2Cl2)
     IC50=87.5 µg/mL
    -  3.0 g
Aralia racemosa
C (Aqueous)
-  74.6 g powdered whole plant
-  Extracted with 80% MeOH
CH2Cl2/H20 Partition (pH 2)
CH2Cl2/H20 Partition (pH 9)
C18 Column Chromatography
 -  Step Gradient
ID#  A1  A2  A3  A4  A5  A6  A7
C18 HPLC
-  84% MeOH
-  67.6 mg
ID#  A4A  A4B  A4C        A4D         A4E  A4F  A4G
Yield (mg): 148.3  64.8  117.4  134.4  523.6  82.2  18.5
MCF-7: NA  5  70  71  68  NA  NA
FS-4:  NA  35  72  73  70  NA  NA
Yield (mg): 9.8  1.8  2.7  2.5  14.2  3.3  31.4
MCF-7: 1  62  68  45  77  24  0
FS-4:  0  79  80  61  80  56  0
ent-kaurane diterpenoid
 -  2.7 mg
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Compound 2.9 was found to give a pseudomolecular ion of m/z 305.1 ([M+H]) 
when examined by low resolution ESI-MS.  1H and 13C NMR data were collected in d-
chloroform (CDCl3) and reported in Table 2.1. The 
1H NMR spectrum of 2.9 showed 
several key proton signals, including two methyl singlets (δH 0.86 and 0.99), an 
oxygenated proton doublet signal (δH 3.39), and an aldehyde proton singlet (δH 9.76).  
The 13C NMR experiment yielded twenty signals.  These signals suggested the presence 
of both an oxygenated carbon and an aldehyde carbon (δC 67.61 and 206.08 respectively).  
A DEPT-135 experiment helped in the determination of the presence of four methines, 
one oxygenated methine, nine methylenes, one oxygenated methylene, two methyls, and 
by comparison with 13C NMR data three quaternary carbons.  The DEPT-135 experiment 
and MS ion helped to drastically reduce the number of chemical formula possibilitie .  
Also, IR analysis provided evidence of an O-H stretch at 3378 cm-1.  Along with the 1H 
NMR data, 13C NMR data, IR, and MS analysis, the compound was determined to have a 
molecular formula of C20H32O2 with a mass of 304.2 g/mol.  Using the molecular 
formula, the degree of unsaturation was determined to be five for compound 2.9. 
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Table 2.1:  13C and 1H NMR Data for 2.9 
 
Position δC
a DEPT-135 δH
a Multiplicity 
1 39.98 CH2 0.80 m 
   1.85 m 
2 18.83 CH2 1.58 m 
3 34.32 CH2 1.00 m 
   2.14 m 
4 48.53 C - - 
5 56.77 CH 1.14 dd, J1=12.3, J2=2.2 
6 20.48 CH2 1.65 m 
   1.86 m 
7 41.65 CH2 1.52 m 
8 44.70 C - - 
9 54.88 CH 1.04 m 
10 39.43 C - - 
11 18.49 CH2 1.46 m 
12 31.31 CH2 1.45 m 
   1.59 m 
13 38.27 CH 2.10 m 
14 37.56 CH2 1.00 m 
   1.84 m 
15 45.16 CH2 0.94 m 
   1.60 m 
16 43.40 CH 1.97 m 
17 67.61 CH2 3.39 m 
   3.42 m 
18 24.39 CH3 0.99 s 
19 206.08 CH 9.76 s 
20 16.40 CH3 0.86 s 
*All units in ppm 
aSpectra were acquired using CDCl3 (d-chloroform) 
 
With the presence of twenty carbons confirmed, a C20 skeletal structure was 
proposed.  The skeleton along with the presence of two methyls, an aldehyde, a hydroxyl 
group, and a high degree of unsaturation with no double bonds, the structure was 
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hypothesized to be an ent-kaurane derivative (2.10), a class of compounds previously 
found in the Aralia genus.   
 
2.10 
A HSQC analysis was performed on compound 2.9 showing carbon-proton one 
bond coupling.  These results are depicted in Table 2.1.  These HSQC correlations 
allowed for the interpretation of the COSY and HMBC spectra. 
 COSY analysis of compound 2.9 suggested the presence of several key structural 
segments that are shown in Figure 2.2.  The proton signal at δH 3.39 ppm was coupled to 
a signal at δH 1.97 ppm.  Due to the multiplicity of the signal at δH 3.39 ppm, it was 
determined to be the methylene attached to the hydroxyl group.   The methine signal at δH 
1.97 ppm showed a correlation to a methylene signal at δH 0.94 ppm.  A crosspeak was 
also observed between the methine and methylene at δH 1.97 and δH 2.10 ppm.  Also a 
crosspeak was observed between the methine and methylene at 1.84 and δH 2.10 ppm.   
This series of correlations established segment A (Figure 2.2). A coupling was also 
observed between the methylene protons at δH 0.80 ppm and 1.58 ppm, and also the 
methylene protons at  δH 1.58 ppm and 2.10 ppm.  These correlations helped to determine 
segment B in Figure 2.2.  COSY correlations can be seen in Figure 2.3.  Other COSY 
correlations were present in the COSY experiment but are also shown in HMBC 
correlations so they are not specifically reported. 
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Figure 2.2:  Structural Segments for 2.9 from the 1H-1H COSY Experiment  
*a = a, b = b, c = c, … 
 
  
 The HMBC spectrum allowed for the determination of the connectivity of the 
previously mentioned structural segments.  Correlations between the methyl signal at δH 
0.99 ppm and the carbon signals at δC 48.53 and 34.32 ppm suggested the connectivity of 
segment B to the methyl through a quarternary carbon at δC 48.53 ppm.  The HMBC also 
allowed for a correlation to be made between the methyl protons at δH 0.99 ppm and the 
carbon at δC 56.77 ppm.  This carbon showed a correlation to the proton signal at δH 0.86 
ppm, a methyl proton attached to the methyl carbon at δC 16.40 ppm in segment B.  The 
b 
a 
 
 
 
c 
 
d 
e 
 
 
 f 
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aldehyde proton at δH 9.76 ppm also showed a correlation to the methylene at δC 34.32 
ppm and the methine at δC 48.53 ppm.  A correlation was also observed between the 
methine proton at δH 1.14 ppm and the aldehyde carbon at δC 206.08 ppm.  These 
correlations provided evidence of segment C in Figure 2.3. 
CH3 CHO
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Figure 2.3:  Segment C of 2.9 
 
 
 
The HMBC spectrum also provided correlations to the hydroxylated carbon (segment A).  
The proton signal of the CH2 group at δH 3.39 ppm shows a correlation to the carbon at δC 
43.40 ppm, and also one to the methylene at δC 45.16 ppm.  The proton at δH 1.97 ppm 
attached to the carbon at δC 43.40 ppm was shown to have a correlation to the carbon at 
δC 38.27 ppm, which also showed a correlation to the proton at δH 1.58 ppm, which is in 
fact part of segment A.  The methylene proton at δH 0.94 ppm showed a correlation to the 
methine at δC 54.88 ppm.  The proton at δH 0.94 ppm also showed a correlation to the 
quaternary carbon at δC 44.70 ppm.  These correlations provided evidence of segment D 
in Figure 2.4.  Additional key 2D information and correlations are shown in Figures 2.6 
and 2.7. 
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Figure 2.4:  Segment D of 2.9 
 
 
 
 In order to see if compound 2.9 was a known compound, a literature search was 
performed for compounds with a molecular formula of C20H32O2 and the presence of a 
substructure similar to segment D.  The search yielded several results, but after refining 
the results to include the presence of an aldehyde and four rings, and taking into 
consideration the isolation of an e t-kaurane derivative in previous work completed on 
the plant in our lab,29 two possibilities were found.  The preliminary data, along with the 
unsaturation number matched well with that of 17-hydroxy-16β-ent-kauran-19-al (2.9), a 
known diterpenoid that has been isolated from similar plant species.  Additional key 
COSY and HMBC correlations are shown in Figures 2.6 and 2.7.   
A discrepancy was found, though, as the orientation of the hydroxyl group on C-
17 in the proposed structure did not match correctly with the published data.31 Further 
investigation of literature related to the Aralia genus and ent-kaurane diterpenoids 
revealed a great bit of confusion in the labeling of similar compounds.  The main 
discrepancies occurred at the location of the hydroxyl group at C-17 and the surrounding 
carbons and hydrogens, due to either incorrect assigning of the carbons in previously 
published work or citations of these publications in subsequent studies.  The discrepancy 
revolves around the chemical shift of C-17 and its orientation in relation to C-11.  Dräger 
et al. summarized the older incorrect assignments and incorrect publications and 
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presented their own case for the correct chemical shifts of the carbons in a supplemental 
paper dealing with diterpenes from the plant Stillingia sanguinolenta.30  The Dräger 
group observed and reported that a structure having the H-16 oriented towards the C-11 
resonates at δH 3.3 ppm, while the C-17 resonates at a frequency of δC 67 ppm.  While the 
epimer with H-16 oriented away from the C-11 resonates at δH 3.7 ppm, and the C-17 is 
shifted upfield around δC 64.0 ppm.  The data in Table 2.1 reports these chemical shifts to 
be δH 3.39 ppm and δC 67.61 ppm respectively.  This data led to our assignment of the H-
16 proton as being oriented towards the C-11 carbon (depicted in Figure 2.5).    
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Figure 2.5:  Possible Orientations of the Hydroxyl Group in Compound 2.9 
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2.9 
Due to budget constraints at the Bent Creek Institute (BCI), compound 2.9 has not 
yet been submitted for assay testing as a pure compound and therefore exact assay data 
cannot be reported.  However, a previous fraction containing compound 2.9 was tested.  
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The results were positive with the semi-pure compound showing 75.7% inhibition of 
MCF-7 cells at 100 µg/mL, and 70.3% inhibition of FS-4 cells at 100 µg/mL.  The 
fraction contained some minor impurities of a falcarindiol derivative with known activity.  
Therefore the activity of compound 2.9 was not able to be confirmed due to the ending of 
our antitumor natural products drug discovery collaboration with BCI.  
It should be noted that several problems arose from the particular MCF-7 assay.  
Several instances of disappearing activity, inconsistent results, and varied protocol were 
observed.  While some of the activity inconsistencies could possibly be due to the 
synergistic effects described in chapter 1, it was hypothesized that the assay itself was 
subject to significant variability.  It would be possible to rule sample degradation out by 
testing for synergism.  An experiment could be performed by initially testing a parent 
fraction and subsequent daughter fractions to see if activity was lost.  If in fact activity 
was lost in the experiment, daughter fractions could be recombined to test if the initial 
parent fraction’s activity can be recovered.  If in fact it is recovered, then synergistic 
effects are most likely the cause for activity loss.  This particular experiment was unable 
to be performed due to monetary and time constraints. 
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Figure 2.6:  Additional COSY Correlations for Compound 2.9 
*a = a, b = b, c = c, … 
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Figure 2.7:  HMBC Correlations of Compound 2.9 
*a = a, b = b, c = c, … 
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2.2.2 Previous Investigation of ent-Kaurane Diterpenoids 
 The Aralia genus is not the only type of plant to produce these ent-kaurane of 
diterpenoids.  The plant Annona squamosa is also documented as producing these types 
of compounds.  Yang-Chang Wu et al.  isolated a number of ent-kauranoic diterpenoids 
from the fruits of Annona squamosa.  Aside from the compound ent-16β,17-
dihydroxykauran-19-oic acid (2.7), the majority of the compounds did not show any 
significant activity in the HIV assay.  ent-16β,17-Dihydroxykauran-19-oic acid was 
identified as showing activity against HIV replication in H9 lymphocyte cells.  The 
compound exhibited an IC50 of 0.263 µM in the assay referenced.
31  Annona squamosa 
has also proved to be moderately effective in anti-platelet aggregation through the studies
of Yu-Liang Yang et al.  Yang et al.  isolated and characterized twenty new and known 
ent-kaurane diterpenoids, two of which were found to inhibit platelet aggregation, the 
previously discussed ent-kaur-16-en-19-oic acid (2.6) and 16α-hydro-19-al-ent-kauran-
17-oic acid (2.8).  The compound 2.8 completely inhibited platelet aggregation induced 
by arachidonic acid and collagen at 200 µM, and compound 2.6 completely inhibited 
platelet aggregation induced by collagen at 200 µM.32   
ent-Kaurenoic acid (2.11) was also previously isolated by the Clement group.29  
The pure compound was isolated from the same acidic extract as compound 2.9, 
following the bioassay-guided fractionation scheme previously reported.  Compound 2.11 
was isolated along with a cytotoxic diterpenoid (2.12).  Compound 2.11 was determined 
to be inactive after bioassay results were received, while 2.12 was reported as inhibiting 
73% of MCF-7 cells at a concentration of 100 µg/mL and inhibiting 73% of FS-4 cells at 
a concentration of 100 µg/mL.29 
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2.3 Experimental 
General Experimental Procedures.   HPLC separations were performed on a Perkin 
Elmer Series 200 Pump and UV/Vis Detector using either a Varian Dynamax 250*10.0 
mm (L*ID) Microsorb 100 Å-5mm C18 with a Varian Dynamax Guard ½” Microsorb 
100-5 C18 guard column or a Varian Dynamax 250*21.4 mm (L*ID) Microsorb 100-5 
C18 with a Varian Dynamax Guard 1” Microsorb 100-5 C18 guard column.  The IR 
spectrum was recorded with a Perkin Elmer Spectrum One FT-IR spectrophotometer.  
NMR spectra were recorded on a JEOL 300 MHz Eclipse + FT NMR with 5mm FG/TH 
Tunable Probe.  Mass spectral data were obtained on a Finnigan LTQ MS-Ion Mass API 
Source operating with a LC Packings Ultimate 3000 using a C18 PepMag 100 3µm 100Å 
15 cm column. 
Plant Material and Sample Preperation. Whole plants were harvested by Josh Kelly in 
rich oak-hickory cove forests in Buncombe County, N.C.  Plant material was ground and 
initially extracted by Ryan M. Kelly of the Bent Creek Institute, at the North Carolina 
Arboretum.  Plants were lyophilized and ground to 250 nm particle size.  Voucher 
samples were collected and stored at the Bent Creek Institute’s Germplasm Repository at 
the North Carolina Arboretum.  The powdered plant material (74.6 g) was extracted with 
40 
 
 
80% MeOH:H2O, filtered, then extracted again with 2:1 CH2 l2:MeOH.  The 80% 
MeOH:H2O extract was concentrated by rotary evaporation to remove the MeOH, and 
the remaining aqueous material was partitioned by an acid-base extraction.  All plant 
material collection and extract preparation was completed by Bent Creek Institute. 
 Isolation and Characterization of 2.9.  The crude extract was subjected to an acid/base 
extraction, and the extract was initially partitioned between CH2Cl2 and H2O (pH 2).  The 
aqueous layer was basified (pH 9), and further partitioned with CH2Cl2.  The remaining 
H2O fraction was set aside as the aqueous fraction.  The CH2Cl2 fraction following 
acidification of this extract was received from Bent Creek Institute under the sample 
number BCI00041B.  Both the acidic fraction and basic fraction showed positive results 
in the MCF-7 assay.  The fraction was selected for further investigation due to the 
partitioning resulting in a greater mass than all other fractions.  The acidic fraction was 
fractionated further by the use of a C18 open column, using various concentrations of 
aqueous methanol as a solvent system.  Four active fractions resulted from the separation.  
The 80% MeOH fraction was selected to continue fractionation based on improved assay 
data.  The 80% MeOH fraction was subjected to repeated C18 reverse-phase HPLC that 
yielded seven fractions.  1H NMR analysis of one of the fractions showed compound 2.9 
present in pure form.  More extract was obtained and fractioned from Bent Creek 
Institute in order to recover enough of compound 2.9 for analysis following the same 
protocols and fractionations. 
Assay Preparation.  High-throughput 96-well format viability assays were used to 
determine the anti-tumor effects of natural product chromatographic fractions.  Breast 
(MCF-7) tumor cells were the representative tumor cell line, while human foreskin 
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fibroblasts (FS4) were the representative non-tumor tissue. MCF-7 and FS4 cells wer  
maintained in Dulbecco's Modified Eagle Medium and 10% Fetal Bovine Serum.  Each 
type of cell was seeded at ~5,000 cells/well in 96-well plates. After seeding for 24-36 
hours, fresh medium was added to the cells in triplicate. Each sample had a three-point 
dilution yielding concentrations of 100 µg/ml, 50 µg/ml, and 10 µg/ml.  After 36 hours 
the viability of each treated group was assessed relative to the control group by the MTS 
assay (Promega®).  The assay measured the cell’s viability through its capability to 
reduce the tetrazolium salt, MTS, into a soluble formazan product that can be 
spectrophotometrically detected at 492 nm. Extracts/Fractions/Compounds that elicit cell 
death or reduced proliferation were detected by a loss of absorbance when compared to 
untreated cells.  
17-Hydroxy-16α-ent-kauran-19-al (2.9): white amorphous powder; IR (neat film) 
3378, 2925, 2852, 1718, 1463, 1369, 1248, 1060, 1019, 970, 906, 890, 763, 738 
cm-1;   1H NMR (CDCl3) see Table 2.1; 13C NMR (CDCl3) see table 2.1; LRESI-
MS (positive ion) 305.1 ([M+H] +, calc. for C20H32O2: 305.2) 
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3. ISOLATION AND CHARACTERIZATION OF 1β-ACETOXY-6α, 7α -
DIANGELOYLOXY-2-OXO-OPLOPA-3, 14Z, 11, 12-DIENE-13-AL, AN 
OPLOPANE DERIVATIVE FROM THE PLANT ARNOGLOSSUM 
ATRIPLICIFOLIUM (CACALIA ATRIPLICIFOLIA) 
 
 
 
3.1 Introduction 
 The plant Arnoglossum atriplicifolium has been studied chemically very little 
throughout history.  Using the breast cancer cell line assay MCF-7, 1β-Acetoxy-6α, 7α-
diangeloyloxy-2-oxo-oplopa-3, 14Z, 11, 12-diene-13-al, an oplopane derivative was 
isolated from an extract of the plant, Arnoglossum atriplicifolium (Cacalia atriplicifolia) 
by bioassay-guided fractionation.  The results for the isolation and characterization of the 
natural product 1β-Acetoxy-6α, 7α-diangeloyloxy-2-oxo-oplopa-3, 14Z, 11, 12-diene-13-
al, are provided below.  The biological activity of the oplopane derivative from 
Arnoglossum atriplicifolium is reported below. 
3.1.1 Previous Investigation into the Arnoglossum (Cacalia) Species 
Previously, the genus Arnoglossum (previously known as Cacalia) has shown 
some promising results in a variety of assays, with activities ranging from anti-fungal and 
anti-malarial properties all the way to anti-tumor activities against certain tumor cell 
types.  The species A. atriplicifolium has been studied very little up to this point from a 
bioactivity standpoint, with research mainly focusing on phytochemical and oil studie .  
The previous history of the genus and compounds found in these types of plants, along 
with the lack of study of the plant Arnoglossum atriplicifolium and its bioactivity 
specifically, make it a prime candidate for our research. 
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The species Arnoglossum (Cacalia) has yielded many different kinds of 
compounds in previous studies, including oplopanes, furans, coumarins, triterpenoids, 
and kaurenoids.  Most of these studies were purely phytochemical while others wer  
based on earlier studies in search of natural sources of both oil and rubber for industrial 
uses.  In a study aimed at isolating oil and rubber compounds out of Cacalia atriplicifolia 
as potential oil and rubber sources, Spencer isolated the compound dammarenediol II 
(3.1).  Around a quarter of the seed oil from Cacalia atriplicifolia is composed of the 
long-chain fatty esters of 3.1.  Also, a small amount of the seed oil was reported to be 
composed of long-chain fatty esters from oleanolic acid.33 
CH3
CH3CH3
CH3 CH3
OH
OH
CH3
CH3
CH3
H
H
H
H
 
3.1 
 The genus Cacalia has also yielded some positive results when tested against 
various bioassays in vitro.  Nishikawa et al. isolated the bisabolane sesquiterpenoid 
endoperoxide, 3,6-Epidoxy-1,10-bisaboladiene (3.2) from the edible wild-plant Cacalia 
delphiniifolia, a plant found commonly in the northern part of Japan.  The group isolated 
3.2 and tested it against both the K562 cell assay (human chronic myelogenous leukemia) 
and the LNCaP cell assay (human prostate carcinoma).  The results were positive 
showing IC50 values to be 9.1 µM and 23.4 µM respectively.  For comparison the group 
ran α-Curcumene (3.3), a known anti-tumor agent commonly found in a large number of 
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plants and essential oils.  Compound 3.3 presents an interesting comparison as it lacks an 
endoperoxide moiety, but aside from the endoperoxide the structure is basically the same.  
When 3.3 was exposed to the same assays, it exhibited over ten times less potency (256.5 
µM and 277.5 µM), suggesting the endoperoxide moiety is indeed a major part of the 
activity of 3.2.34 
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The species C. atriplicifolia (A. atriplicifolium) has also been studied from a 
phytochemical standpoint.  Bohlmann et al. isolated a series of highly oxygenated 
oplopane derivatives.  Bohlmann’s group was in an ongoing investigation into the tribe 
Senecionea, which led to their study of the aerial parts of Arnoglossum atriplicifolium.  
The oplopane derivatives (3.3, 3.4, 3.5, 3.6, 3.7) were reported with their respective 1H
NMR data.35 
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3.2 Results and Discussion 
3.2.1 Isolation and Characterization of 3.8 
 Isolation of 1β-Acetoxy-6α, 7α-diangeloyloxy-2-oxo-oplopa-3, 14Z, 11, 12-diene-
13-al (3.8) is given in Figure 3.1.  An acidic fraction of Arnoglossum atriplicifolium (see 
section 2.3 for the protocol for sample preparation) was initially found to be activein 
BCI’s antitumor assay screening, with 89% inhibition of MCF-7 cell proliferation at 125 
µg/mL. The Arnoglossum atriplicifolium crude extract subsequently generated by organic 
solvent extraction showed promising activity in the MCF-7 cell assay, with an IC50 = 19.0 
µg/mL.  The crude extract was then subjected to a modified Kupchan partitioning, 
resulting in four fractions, two of which were active.  After bioassay guided fractionation 
by reverse phase C18 open column chromatography, reverse phase C18 HPLC, and normal 
phase SiO2 HPLC on active fractions, 3.8 was isolated as the most active fraction in the 
crude sample.  Due to the small sample size of 3.8 that prevented in depth analysis, more 
of the compound needed to be isolated.  In a simultaneous bioassay guided experiment 
conducted in the Clement Lab, two undergraduate students isolated compound 3.8 from 
the hexane fraction in greater yield from a fraction generated at BCI.  After comparison 
of the samples by 1H NMR analysis it was determined that the compounds were the same 
and analysis was continued with the sample of greater mass.   
1H and 13C NMR data were collected in d-chloroform (CDCl3) and also d-benzene 
(C6H6) and reported in Table 3.1.  The 
1H NMR spectrum of 3.8 showed several key 
proton signals.  These included an acetate methyl singlet (δH 2.09), two epoxide doublets 
(δH 2.84 and 3.06), an aldehyde singlet (δH 9.64), and several doublets of quartets (δH 
1.89 and 2.01) and quartets of quartets (δH 6.03 and 6.17).   The 
13C NMR experiment 
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yielded twenty-three signals in CDCl3.  Key signals observed included two carbonyls at 
δC 193.26 and 199.07 ppm, several sp
2 alkene carbon signals, and several oxygenated 
carbon signals.  Two of the oxygenated carbons appeared to be part of an epoxide as the 
chemical shifts of the signals, were shifted downfield to δC 50.97 and 56.98 ppm. The 
1H 
spectra also showed two doublets at δH 2.84 and 3.06 ppm, which confirmed the presence 
of an epoxide in compound 3.7.  A DEPT-135 experiment helped in the determination of 
the presence of at least eight methines, one methylene, and six methyls.  A HSQC 
analysis was also performed on compound 3.8 showing carbon-proton one bond 
coupling.  These results are depicted in Table 3.1. These HSQC correlations allowed for 
the interpretation of the HMBC spectra.  Further investigation of the 13C spectrum 
revealed that several carbon signals were not appearing in the spectra due to 
conformational issues, and possible overlapping of signals.  A prime example of these 
discrepancies were the presence of three esterified methine protons in the 1D sp ctrum, 
while only two oxygenated carbons were observable in the 13C spectrum.  Several signals 
were observed in the HSQC and HMBC spectra that were not clearly observable in the 
1H spectrum.  The conformational issues will be addressed later in this section.  These 
issues were handled in order to confirm the structure. 
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Arnoglossum atriplicifolium
Hexane Frax
Cl2CH2
Modified Kupchan Partition
Hexane:::60% MeOH:H2O Partition
C18 Column Chromatography
 -Step Gradient
-1.59 g
MCF-7 60
FS-4  67
ID#  A1  A2  A3  A4  A5  A6  A7
C18 Column Chromatography
 -72% MeOH(aq):H2O Isocratic
-20 Frax collected and reconstituted 
to 5 total frax
ID#  A3A  A3B  A3C        A3D         A3E  A3F
50% MeOH:H2O:::CH2Cl2 Partition
BuOH:H2O Partition
BuOH Frax H2O Frax
HPLC 77% MeOH(aq)
- 11.1 mg
ID#  A3E1 A3E2 A3E3       A3E4         A3E5  A3E6  A3E7 
MCF-7 17  76  80  78  72  NA  NA
FS-4  14  73  80  80  66  NA  NA
MCF-7 32  59  NA  60  59  25  
FS-4  38  59  NA  59  59  35
Mass (mg):  212.4         66.8  535.7  128.6  76.6  212.5  NA
Mass (mg): 317.1 50.2  42.4  25.4  65.8  16.9
Mass (mg):  2.3  1.3  1.5  .8  1.1  1.0  1.5
MCF-7 NT  NT  NT  NT  NT  NT  NT
FS-4  NT  NT  NT  NT  NT  NT  NT
Oplopane Derivative
MCF-7 63
FS-4  67
*Unless otherwise noted, all 
assay samples tested at           
100 µg/mL
Figure 3.1:  Isolation of Compound 3.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
 
Table 3.1:  13C and 1H NMR Data for 3.8 
 
 
 δC
a DEPT-135 δH
a  δH
b  
1 70.99 CH 5.13 d, J1 = 3.1 5.07 d, J1 = 4.8 
2 199.07 C - - - - 
3 136.23 C - - - - 
4 + CH + - + - 
5 + CH + - 3.71 m 
6 + CH 5.30 bs 5.47 dd, J1 = 11.0, J2 =3.0 
7 74.02 CH 4.86 d 5.17 d, J1 = 3.1 
8 56.98 C - - - - 
9 42.20 CH 2.47 dd, J1 = 5.2, J2 = 2.0 2.34 dd, J1 = 12.9, J2 =4.8 
10 50.97 CH2 2.84 d, J = 4.5 2.93 d, J1 = 4.8 
    3.06 d, J = 4.5 2.62 d, J1 = 4.6 
11 + C - - - - 
12 136.23 CH2 6.29 s 5.75 s 
    6.63 - 5.38 s 
13 193.26 CH 9.64 s 9.20 s 
14 138.32 CH 5.90 bs 5.79 m 
15 15.10 CH3 2.08 dd,  J1 = 5.2, J2 = 2.0 1.92 m 
Ang1 1 166.04 C - - - - 
Ang2 1 166.01 C - - - - 
Ac 1 170.01 C - - - - 
Ang1 2 127.16 C - - - - 
Ang2 2 126.81 C - - - - 
Ac 2 21.02 CH3 2.09 s 1.74 s 
Ang1 3 140.13 CH 6.17 qq, J1 = 7.2, J2 = 1.3 5.77 m 
Ang2 3 140.39 CH 6.03 qq, J1 = 7.2, J2 = 1.4 5.68 dq, J1 = 7.0, J2 = 1.5 
Ang1 4 20.42 CH3 1.97 m 1.95 m 
Ang2 4 20.88 CH3 1.67 m 1.72 m 
Ang1 5 16.20 CH3 2.01 dq, J1 = 7.3, J2 = 1.5 1.97 dq, J1 = 7.7, J2 = 1.5 
Ang2 5 15.90 CH3 1.89 dq, J1 = 7.4, J2 = 1.5 1.87 dq, J1 = 7.0, J2 = 1.6 
*All units in ppm 
 aSpectra were acquired using CDCl3 (d-chloroform) 
bSpectra were acquired using C6D6 (d-benzene) 
+ = signal unobservable in spectrum 
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Low resolution positive ion ESI-MS of compound 3.8 gave a pseudomolecular 
ion of m/z 501.4 ([M+1]) when examined.  Upon analysis of 1H, 13C, DEPT-135, HSQC 
NMR data, and MS data for 3.8 it was determined that compound 3.8 was very similar to 
compound 3.7 reported by the Bohlmann group as mentioned in section 3.1.  Compound 
3.7 was also reported with a molecular ion of 500.2 m/z ([M+]) with molecular formula of 
C27H32O9, further providing clues that there were missing carbons in the 
13C NMR data 
for compound 3.7.  The molecular formula of compound 3.8 could not be C27H32O9 with 
the nnumber of carbons observed in the 13C spectra.  Due to chemical shift similarities at 
the protons on C-5, C-10, C-13, C-15, C-21, along with several others between 
compound 3.8 and the Bohlmann compound 3.7, it was hypothesized that compound 3.8
had a chemical formula of C27H32O9  with a mass of 500.4 g/mol, and was most likely the 
same as compound 3.7.  From this information it was also deduced that compound 3.8 
had a degree of unsaturation of eleven rings plus double bonds. The remaining step was 
to use 2D NMR data to confirm whether compound 3.8 was the same as 3.7.  Working 
under the hypothesis that compound 3.8 was the same as the published Bohlmann 
compound 3.7, 1H-1H COSY correlations and HMBC correlations were examined to see 
if the compounds were indeed the same to test the hypothesis. 
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Several COSY correlations were found that pieced together each of the angeloxy 
groups as seen in Segment A.  Coupling was observed between the methine group at δH 
6.03 and the methyl group at δH 1.89, in the angeloxy group.  A coupling was also 
observed between these two methyl groups at δH 1.67 and 1.89.  HMBC correlations were 
also observed in the angeloxy groups, specifically between the quaternary carbon at δC 
126.81 and the methyl protons at δH 1.67 and 1.89.  A correlation was also observed 
between the quaternary carbon at δC 126.81 and the methine at δH 6.03.  Also, a second 
quaternary carbon at δC 166.01 was observed as correlating to the methyl proton at δH 
1.67.  A second angeloxy group was also observed that showed similar correlations, in 
both the HMBC and COSY at similar chemical shifts.  These correlations, seen in Figure 
3.3, helped establish the presence of two angeloxy groups in compound 3.8. 
The conformational issues previously mentioned were resolved by running 
addition NMR experiments in d-benzene at 70° C.  These parameters allowed for 
compound 3.8 to achieve a single energy state as opposed to the many different energy 
states that were present under normal conditions.  The presence of a single ener y state 
allowed for the resolution of several signals in compound 3.8 that are depicted in Table 
3.1.   
  A signal for the methine where the angeloxy group was connected to the rest of 
the skeleton of compound 3.8 also provided a clue as to the orientation of compound 3.8.  
The methine proton at δH 4.86 showed a HMBC correlation to the quaternary carbon at δC 
56.98, suggesting the epoxide was located near the angeloxy group.  These correlations, 
seen in Figure 3.2, along with the detected epoxide and angeloxy groups suggested a 
fragment such as segment B was present in compound 3.8.  The segment also suggests 
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that, if the Bohlmann structure is correct, C-5, C-6, and C-11 were not showing up in the 
spectra as they were not present in the 13C spectrum nor showing any correlations in the 
2D spectra.   
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3.8 
Finally the assignments of the ketone and acetyl groups needed to be addressed.  
The acetoxylated methine group at δH 5.13 was found to be coupled with the methine at 
δH 2.47 through a COSY correlations, showing that the two methine groups are next to 
each other.  The methyl proton signal at δH 2.08 was found to be coupled with the 
methine proton at δH 5.90 in COSY, indicating the position of one of the carbon-carbon 
double bonds in the group.  HMBC analysis, shown in Figure 3.4, showed correlations 
between the acetyl methyl proton at δH 2.09 and the quaternary carbon at δC 170.01, 
suggesting the presence of an acetate group in compound 3.8.  The quaternary carbon at 
δC 170.01 also showed a correlation to the methine proton at δH 5.13, strongly suggesting 
the assignment of the acetyl group.  A correlation was also found between the quaternary 
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carbon at δC 136.23 and the methyl proton at δH 2.08, suggesting the methyl group is 
connected to the methine carbon of the C-C double bond.  Also a key correlation could be 
observed to the ketone at δC 199.07 to the acetoxylated methine group at δH 5.13, 
confirming the location of the ketone and assignment of segment C.  
In order to piece together segments B and C, a correlation was observed between 
the methine proton at δH 5.13 and the methine carbon at δC 74.02.  This correlation 
provided a direct correlation between segment B and C, strongly suggesting that 
segments B and C were connected.  These correlations along with the COSY data 
suggested the epoxide was located between the acetate and angeloxy substituents.  These 
connections showed evidence of 3.8, which was in accordance with the published 
Bohlmann et al. compound.  Complete COSY and HMBC data are provided in Figures 
3.2 and 3.3. 
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Figure 3.3:  Proposed Structure of Compound 3.8
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Figure 3.4:  HMBC and COSY correlations of compound 3.8
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Upon deeper investigation of the proton spectrum an important element was 
absent.  The doublet of doublets that would be expected to be present representing the C-
6 angeloxy group being split by both the C-5 and C-7 methine protons connecting the 
was not observed in the 1H spectum.  Several broad one-proton signals were observed in 
the region where this signal would be expected to appear.  Upon further study of the 
Bohlmann et al. paper it was discovered that running the sample in d-benzene (C6D6) at a 
temperature of 70° C can result in improved spectrum and resolved peaks.  This was 
reported in the Bohlmann et al. paper, as they were experiencing the same difficulties 
with broad singlets and unresolved peaks.  After running the sample under these 
conditions a doublet of doublets was observed at δH 5.62.  These peaks along with the 
subsequent comparison of all proton data, in both C6D6 and CDCl3, further validated the 
proposed structure of the compound isolated (3.8).  The absolute configuration for 
compound 3.8 was not determined, nor was it reported by Bohlmann et al. 
Several attempts were made to improve upon the data set using the 300 MHz 
instrument with a direct probe.  The direct probe (proton observe coil on outside of 
probe) causes an increase in proton signal to noise.  This signal to noise increase on 
proton spectra proved to be problem in our work as many spectra were not as clear.   
Initially compound 3.8 was run at increased scans in order to improve signal to noise 
strength, to no avail.  Several alternate 2D experiments including a NOE experiment, 
which measures proton coupling through space, to see if any additional cross peaks could 
be observed that would provide any information as to the orientation of compound 3.8.  
The NOE also failed to provide any relevant information or peaks that would be expected 
from the spectrum.   Also implemented was the use of a Shigemi® tube, a piece of 
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equipment that allows for a smaller solvent volume to be used, therefore increasing 
sample concentration.  After implementation of a Shigemi® tube run at increased scns 
(experiments ranged from 12 to 36 hrs), some improvement was observed, but peaks 
were obviously still not resolved or showing up.  In an attempt to acquire an improved 
data set for compound 3.8, the compound was sent to a collaborator at Youngstown State 
in Ohio, with access to a 400 MHz NMR with an indirect probe.  The higher field NMR 
should, in theory, improve upon the data set and possibly resolve peaks that the 300 MHz 
was unable to improve upon, while the indirect probe (proton observe coil on inside of 
probe) should allow for better resolution of the proton spectra.  Upon receiving the 
outsourced spectra from the higher field NMR, no real improvement was observed and no 
further key correlations could be found.  These failed attempts at trying to acquire better 
data for compound 3.8 led the group to believe that the best resource in deciphering the 
structure of compound 3.8 the previously used Bohlmann et al. paper, specifically using 
compound 3.7, the 1β-Acetoxy-6α, 7α-diangeloyloxy-2-oxo-oplopa-3, 14Z, 11, 12-diene-
13-al. 
In order to obtain an improved data set, simply more of compound 3.8 would need 
to be isolated from the CH2Cl2 and hexane fractions of Arnoglossum atriplicifolium.  Due 
to insufficient material mass provided from Bent Creek Institute and time and monetary 
constraints, this task was unable to be performed.  Future plans include the isolation of 
more of the compound and determine the absolute configuration of compound 3.8.     
Compound 3.8 was determined to be the most active compound in the organic 
extract of Arnoglossum atriplicifolium.  Compound 3.8 was found to inhibit 62.6% of 
MCF-7 cells at 100 µg/mL and 66.6% of FS-4 cells at the same concentration.  The IC50 
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of compound 3.8 was determined to be 19.02 µg/mL.  This is the first report of antitumor 
activity of a purified compound from the plant Arnoglossum atriplicifolium.   
3.2.2 Previous Investigation of Oplopane Derivatives 
These types of oplopane derivatives have also been found in other plant species, 
such as Acrisione denticulata.    Abdel Aal et al. isolated a total of eleven new oplopane 
derivatives and a new furolabdane from an extract of the aerial parts of Acrisione 
denticulate (Senecio yegua).  The genus Acrisione is believed to be part of the same 
subtribe (Tussilagininae) as Arnoglossum (Cacalia), which the chemistry supports.  The 
oplopanes reported had three main structures with several derivatives, 3.9 - 3.20.36 
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3.3 Experimental 
General Experimental Procedures.   HPLC seperations were performed on a Perkin 
Elmer Series 200 Pump and UV/Vis Detector using either a Varian Dynamax 250*10.0 
mm (L*ID) Microsorb 100-5 C18 with a Varian Dynamax Guard ½” Microsorb 100-5 
C18 guard column or a Varian Dynamax 250*21.4 mm (L*ID) Microsorb 100-5 C18 
with a Varian Dynamax Guard 1” Microsorb 100-5 C18 guard column.  IR spectra were 
recorded with a Perkin Elmer Spectrum One FT-IR spectrophotometer.  NMR spectra 
were recorded on a Jeol 300 MHz Eclipse + FT NMR with 5mm FG/TH Tunable Probe.  
Mass spectral data were obtained on a Finnigan LTQ MS-Ion Mass API Source operating 
with a LC Packings Ultimate 3000 using a C18 PepMag 100 3µm 100Å 15 cm column. 
Plant Material and Sample Preperation.  Whole plants of Arnoglossum atriplicifolium 
were wild-harvested by botanist Josh Kelly, in rich cove forests of 3000-4000 ft elevation 
throughout Buncombe County, N.C.  Voucher samples were collected and stored at the 
Bent Creek Institute’s Germplasm Repository at the North Carolina Arboretum.  Plant 
material was ground and extracted by Ryan M. Kelly of the Bent Creek Institute, either at 
the N.C. Arboretum or at Western Carolina University.  Finely ground plant material was 
suspended in CH2Cl2:MeOH (1:1) overnight, at a ratio of 1 g plant material per 50 ml 
solvent.  The resulting solution was then filtered, and the filtercake was resuspended in 
100% methanol and left for 30 minutes.  The MeOH extraction was filtered and 
combined with the CH2Cl2:MeOH solution and dried to produce the crude extract.  Using 
a separate approach, additional plant material was extracted using pure CH2Cl2, followed 
by pure MeOH.  The MeOH and CH2Cl2 extractions were then combined to produce 
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another crude extract.  Extraction of approximately 240 g of powdered root material by 
these two methods yielded approximately 20 g of crude organic extract. 
Isolation and Characterization of 3.8.  The crude extract was subjected to a modified 
Kupchan Partitioning, where the crude extract was partitioned between hexane and 60% 
MeOH/H2O solution with the hexane fraction being set aside.  Water was added to the 
remaining 60% MeOH (aq) mixture to make it 50% MeOH (aq), which was then 
subjected to a liquid partition with CH2Cl2, with the CH2Cl2 fraction set aside.  The 
remaining MeOH was then rotovapped away to leave an aqueous solution.  The aqueous 
solution was then washed with three aliquots of BuOH and separated out, to leave a 
BuOH fraction and aqueous fraction for a total of four fractions.  The crude extract of the 
plant was received from Bent Creek Institute under the sample number BCI00041 II and 
BCI00041IV.  Both the hexane fraction and dichloromethane fractions showed positive 
results in the MCF-7 assay.  The CH2Cl2 fraction was further fractionated by the use of a 
C18 open column, using various concentrations of MeOH/ H2O as a solvent system.  Four 
active fractions resulted from the separation.  The most active fraction, the 70% MeOH 
wash, was further fractionated through C18 open column chromatography using C18 TLC 
of 72% MeOH/H2O to give a good overall separation of sample components, resulting in 
twenty fractions which were reconstituted into five total fractions. Three active fractions 
resulted from the separation.  The 100% MeOH wash was selected for further 
fractionation based on total mass and activity.  The 100% MeOH wash was then 
subjected to a C18 reverse-phase HPLC method of 77% MeOH/H2O that yielded eight 
fractions, two of which were active.  After a “clean-up” step of SiO2 HPLC at 90% 
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Hexane/IPA, 1H NMR analysis of one of the fractions showed compound 3.8 present in 
pure form. 
Assay Preparation.  See section 2.3. 
1β-Acetoxy-6α, 7α-diangeloyloxy-2-oxo-oplopa-3, 14Z, 11, 12-diene-13-al (3.8): 
white amorphous powder; IR (neat film) 2927, 1725, 1645, 1457, 1371, 1225, 
1154, 1044, 969, 849 cm-1; 1H NMR (CDCl3) see Table 3.1; 13C NMR (CDCl3) 
see table 3.1; LRESI-MS (positive ion) 501.4 ([M+H]+, calc. for C27H32O9: 501.2) 
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Appendix A:  1H and 13C NMR Spectra for Compound 2.10 
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DEPT-135 Spectrum in d-chloroform 
 
COSY Spectrum in d-chloroform 
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HMBC Spectrum in d-chloroform 
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HSQC Spectrum in d-chloroform 
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1H and 13C NMR Spectra for Compound 3.8 
O
O
CH2
CH3
AcO
CHO
OAng
OAng
H
H
 
 
 
1H Spectrum in d-benzene 
 
 
 
 
 
 
 
 
 
71 
 
 
1H Spectrum in d-chloroform 
 
 
 
13C Spectrum in d-chloroform 
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DEPT-135 Spectrum in d-chloroform 
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HSQC Spectrum in d-chloroform 
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HMBC Spectrum in d-chloroform 
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